Immune‐Mediated Liver Injury From Checkpoint Inhibitor: An Evolving Frontier With Emerging Challenges
Liver International · 2025-02 · 45 (2)
DOI: 10.1111/liv.16198 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Liver International, online erschienen am 27.01.2025. Verfasst von Lily Dara und 1 weiteren Autor:innen. Beteiligte Einrichtung: Research Center for Liver Disease, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Chemical and Drug Induced Liver Injury, Neoplasms. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Over the past decade, immune checkpoint inhibitors (ICIs) have transformed the treatment of cancer, though they come with the risk of immune‐related adverse (irAEs) events such as hepatotoxicity or Immune‐mediated Liver Injury from Checkpoint Inhibitors (ILICI). ILICI is a serious irAE that, when severe, requires cessation of ICI and initiation of immunosuppression. Cytotoxic T Lymphocytes (CTLs) play a central role in ILICI; however, they are just part of the picture as immunotherapy broadly impacts all aspects of the immune microenvironment and can directly and indirectly activate innate and adaptive immune cells. Clinically, as our understanding of this entity grows, we encounter new challenges. The presentation of ILICI is heterogeneous with respect to latency, pattern of injury (hepatitis vs. cholangitis) and severity. This review focuses on our knowledge regarding risk factors, presentation and treatment of ILICI including ILICI refractory to steroids. An emerging topic, the possibility of rechallenge while accepting some risk, in patients who experience ILICI but require immunotherapy, is also discussed. This review provides an update on the current knowns and unknowns in ILICI and highlights several knowledge gaps where studies are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Center for Liver Disease, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.
- APHP, Hôpital Paul-Brousse, Centre Hépato-Biliaire, Inserm, Unité 1193, Université Paris-Saclay, FHU Hepatinov, Villejuif, France.
ORCID-Profile: Lily Dara
Zitieren
APA
Dara, L., & De Martin, E. (2025). Immune‐Mediated Liver Injury From Checkpoint Inhibitor: An Evolving Frontier With Emerging Challenges. Liver International, 45(2). https://doi.org/10.1111/liv.16198
Vancouver
Dara L, De Martin E. Immune‐Mediated Liver Injury From Checkpoint Inhibitor: An Evolving Frontier With Emerging Challenges. Liver International. 2025;45(2). doi:10.1111/liv.16198
BibTeX
@article{Dara2025,
author = {Dara, Lily and De Martin, Eleonora},
title = {Immune‐Mediated Liver Injury From Checkpoint Inhibitor: An Evolving Frontier With Emerging Challenges},
journal = {Liver International},
year = {2025},
volume = {45},
number = {2},
doi = {10.1111/liv.16198}
}
EUVIMED